Study Evaluating Etanercept in Moderate to Severe Asthma

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Moderate to severe persistent asthma for at least 1 year

• Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted

• Subjects must be on a high-dose inhaled corticosteroid (ICS)

Exclusion Criteria:

• Previous treatment with etanercept

• Current use of cigarettes

• Significant concurrent medical conditions at the time of screening